+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Helix BioPharma Corp (HBP) - Financial and Strategic SWOT Analysis Review

Helix BioPharma Corp (HBP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. The company develops drug candidates for the prevention and treatment of cancer. It develops drugs based on DOS47, its proprietary broad anti-cancer therapeutic platform. DOS47 has yielded two new drug product candidates, V-DOS47 and L-DOS47. V-DOS47 uses the company’s proprietary DOS47 technology conjugated to VEGFR target wide range of cancers and L-DOS47 is designed to treat inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer(NSCLC). It also continues to actively pursue additional novel antibody based technologies for cell-based therapies. Helix is headquartered in Ontario, Canada.

Helix BioPharma Corp Key Recent Developments

Nov 07,2023: Helix and Cone Health Launch Population Genomics Initiative
Aug 22,2023: Helix BioPharma Announces Closing of Private Placement of CAD $3 Million and Board Changes
Jun 14,2023: Helix BioPharma Announces Fiscal 2023 Third Quarter Results
Mar 15,2023: Helix Biopharma Corp. Announces Fiscal 2023 Second Quarter Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Helix BioPharma Corp - Key Facts
  • Helix BioPharma Corp - Key Employees
  • Helix BioPharma Corp - Key Employee Biographies
  • Helix BioPharma Corp - Major Products and Services
  • Helix BioPharma Corp - History
  • Helix BioPharma Corp - Company Statement
  • Helix BioPharma Corp - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Helix BioPharma Corp - Business Description
  • R&D Overview
  • Helix BioPharma Corp - Corporate Strategy
  • Helix BioPharma Corp - SWOT Analysis
  • SWOT Analysis - Overview
  • Helix BioPharma Corp - Strengths
  • Helix BioPharma Corp - Weaknesses
  • Helix BioPharma Corp - Opportunities
  • Helix BioPharma Corp - Threats
  • Helix BioPharma Corp - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Helix BioPharma Corp, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Nov 07, 2023: Helix and Cone Health Launch Population Genomics Initiative
  • Aug 22, 2023: Helix BioPharma Announces Closing of Private Placement of CAD $3 Million and Board Changes
  • Jun 14, 2023: Helix BioPharma Announces Fiscal 2023 Third Quarter Results
  • Mar 15, 2023: Helix Biopharma Corp. Announces Fiscal 2023 Second Quarter Results
  • Dec 14, 2022: Helix BioPharma Announces Fiscal 2023 First Quarter Results
  • Dec 08, 2022: Helix Biopharma Announces Board & Management Changes
  • Nov 01, 2022: Helix Biopharma Announces Fiscal 2022 Year-end Results
  • Nov 01, 2022: Helix Biopharma Corp announces fiscal 2022 year-end results
  • Sep 01, 2022: Helix Biopharma Appoints Gabrielle M Siegers as the Head of Research & Development
  • Apr 18, 2022: Helix Biopharma announces appointment of permanent CEO and Independent Board Members
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact Us
  • Disclaimer
List of Tables
  • Helix BioPharma Corp, Key Facts
  • Helix BioPharma Corp, Key Employees
  • Helix BioPharma Corp, Key Employee Biographies
  • Helix BioPharma Corp, Major Products and Services
  • Helix BioPharma Corp, History
  • Helix BioPharma Corp, Subsidiaries
  • Helix BioPharma Corp, Key Competitors
  • Helix BioPharma Corp, Ratios based on current share price
  • Helix BioPharma Corp, Annual Ratios
  • Helix BioPharma Corp, Annual Ratios (Cont...1)
  • Helix BioPharma Corp, Interim Ratios
  • Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Helix BioPharma Corp, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Helix BioPharma Corp, Ratio Charts
  • Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Merck & Co Inc
  • Photocure Inc
  • Bristol-Myers Squibb Co
  • X4 Pharmaceuticals Inc
  • GlaxoSmithKline Inc
  • Nanovir LLC
  • Merck & Co Inc
  • Bristol-Myers Squibb Co
  • GlaxoSmithKline Inc
  • Nanovir LLC
  • X4 Pharmaceuticals Inc
  • Photocure Inc